Sagimet Biosciences Inc.

For the period ended Jun 30, 2025. Filed Aug 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 13, 2025

SGMT$10.89+0.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (unaudited)

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except for share and per share amounts)


· Three Months Ended June 30, · · Six Months Ended June 30,
· · 2025 · 2024 · 2025 · 2024
Operating expenses:
Research and development	$7,248	6,313	$22,590	$11,575
General and administrative	4,677	4,276	9,200	7,782
Total operating expenses	11,925	10,589	31,790	19,357
Loss from operations	(11,925)	(10,589)	(31,790)	(19,357)
Other income:
Interest income and other, net	1,539	2,471	3,228	4,610
Total other income	1,539	2,471	3,228	4,610
Net loss	$(10,386)	$(8,118)	$(28,562)	$(14,747)

Net loss per share of Series A and Series B common stock outstanding, basic and diluted	$(0.32)	$(0.25)	$(0.89)	$(0.48)
Weighted-average shares of Series A and Series B common stock outstanding, basic and diluted	32,195,366	31,913,887	32,195,355	30,476,657

Net loss	$(10,386)	$(8,118)	$(28,562)	$(14,747)
Other comprehensive loss:
Net unrealized loss on marketable securities	(45)	(30)	(154)	(53)
Total comprehensive loss	$(10,431)	$(8,148)	$(28,716)	$(14,800)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.